(Q38618922)

4 September 2017

CRISPR/Cas9-based tools for targeted genome editing and replication control of HBV. (English)

1 reference

4 September 2017

0 references

0 references

Cheng Peng

1

1 reference

4 September 2017

Mengji Lu

series ordinal

2

1 reference

4 September 2017

Dongliang Yang

series ordinal

3

1 reference

4 September 2017

22 October 2015

1 reference

4 September 2017

1 reference

4 September 2017

30

1 reference

4 September 2017

5

1 reference

4 September 2017

317-325

1 reference

https://scigraph.springernature.com/pub.10.1007/s12250-015-3660-x

4 September 2017

0 references

cites work

Immune responses in liver-directed lentiviral gene therapy.

1 reference

https://api.crossref.org/works/10.1007%2FS12250-015-3660-X

The AAV vector toolkit: poised at the clinical crossroads

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-015-3660-X

Hepatitis B virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-015-3660-X

Interplay between hepatitis B virus and the innate immune responses: implications for new therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-015-3660-X

Multiplex genome engineering using CRISPR/Cas systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-015-3660-X

Molecular biology of the hepatitis B virus for clinicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-015-3660-X

Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-015-3660-X

Genome editing. The new frontier of genome engineering with CRISPR-Cas9

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-015-3660-X

Native hepatitis B virions and capsids visualized by electron cryomicroscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-015-3660-X

Orthogonal Cas9 proteins for RNA-guided gene regulation and editing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-015-3660-X

High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-015-3660-X

Improving CRISPR-Cas nuclease specificity using truncated guide RNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-015-3660-X

The molecular biology of the hepatitis B viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-015-3660-X

The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-015-3660-X

Gene therapeutic approaches to inhibit hepatitis B virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-015-3660-X

Update on Hepatitis B Virus Infection: Focus on Treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-015-3660-X

A guild of 45 CRISPR-associated (Cas) protein families and multiple CRISPR/Cas subtypes exist in prokaryotic genomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-015-3660-X

Role of hepatitis B virus DNA integration in human hepatocarcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-015-3660-X

CRISPR/Cas, the immune system of bacteria and archaea

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-015-3660-X

Immune-modulators to combat hepatitis B virus infection: From IFN-α to novel investigational immunotherapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-015-3660-X

A general chemical method to regulate protein stability in the mammalian central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-015-3660-X

CRISPR/Cas9 nickase-mediated disruption of hepatitis B virus open reading frame S and X.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-015-3660-X

Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-015-3660-X

Bacterial CRISPR/Cas DNA endonucleases: A revolutionary technology that could dramatically impact viral research and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-015-3660-X

Two-stage treatment with hepatectomy and carbon-ion radiotherapy for multiple hepatic epithelioid hemangioendotheliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-015-3660-X

Research highlights for issue 6: the CRISPR/Cas revolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-015-3660-X

Current and future antiviral drug therapies of hepatitis B chronic infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-015-3660-X

Control of cccDNA function in hepatitis B virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-015-3660-X

The CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-015-3660-X

New therapeutic vaccination strategies for the treatment of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-015-3660-X

Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-015-3660-X

RNA-guided human genome engineering via Cas9

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-015-3660-X

Bacterial nonhomologous end joining requires teamwork

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-015-3660-X

Combinations of eight key mutations in the X/preC region and genomic activity of hepatitis B virus are associated with hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-015-3660-X

CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-015-3660-X

In vivo genome editing using Staphylococcus aureus Cas9

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-015-3660-X

Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-015-3660-X

The therapeutic application of CRISPR/Cas9 technologies for HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-015-3660-X

Targeted DNA mutagenesis for the cure of chronic viral infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-015-3660-X

Molecular biology of hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-015-3660-X

Targeting Hepatitis B Virus With CRISPR/Cas9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-015-3660-X

Intracellular context affects levels of a chemically dependent destabilizing domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-015-3660-X

Genome-scale CRISPR-Cas9 knockout screening in human cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-015-3660-X

Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-015-3660-X

Homologous recombination near and far from DNA breaks: alternative roles and contrasting views

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-015-3660-X

Damaging the Integrated HIV Proviral DNA with TALENs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-015-3660-X

Molecular functions and biological roles of hepatitis B virus x protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-015-3660-X

Dimeric CRISPR RNA-guided FokI nucleases for highly specific genome editing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-015-3660-X

Analysis of CRISPR in Streptococcus mutans suggests frequent occurrence of acquired immunity against infection by M102-like bacteriophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-015-3660-X

One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-015-3660-X

Dual gRNAs guided CRISPR/Cas9 system inhibits hepatitis B virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-015-3660-X

Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-015-3660-X

DNA double-strand break repair: all's well that ends well

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-015-3660-X

Cas9-based tools for targeted genome editing and transcriptional control.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-015-3660-X

Molecular determinants of hepatitis B and D virus entry restriction in mouse sodium taurocholate cotransporting polypeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-015-3660-X

One-step generation of mice carrying reporter and conditional alleles by CRISPR/Cas-mediated genome engineering

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-015-3660-X

Persistence of hepatitis B virus covalently closed circular DNA in hepatocytes: molecular mechanisms and clinical significance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-015-3660-X

Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-015-3660-X

Harnessing the clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated Cas9 system to disrupt the hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-015-3660-X

The CRISPR/Cas9 system inactivates latent HIV-1 proviral DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12250-015-3660-X

Novel therapeutic approaches for hepatitis B virus covalently closed circular DNA

21 January 2018

1 reference

12 December 2020

Optimization of a multiplex CRISPR/Cas system for use as an antiviral therapeutic

1 reference

12 December 2020

Targeted genomic rearrangements using CRISPR/Cas technology

1 reference

12 December 2020

Inhibition of hepatitis B virus by the CRISPR/Cas9 system via targeting the conserved regions of the viral genome

1 reference

12 December 2020

Hepatitis B virus: where do we stand and what is the next step for eradication?

1 reference

12 December 2020

Tailor-made CRISPR/Cas system for highly efficient targeted gene replacement in the rice blast fungus.

1 reference

12 December 2020

CRISPR/Cas faces the bioethics spotlight.

1 reference

12 December 2020

Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013.

1 reference

12 December 2020

HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B.

1 reference

12 December 2020

10.1007/S12250-015-3660-X

Identifiers

DOI

1 reference

Dimensions Publication ID

4 September 2017

0 references

1 reference